Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Human herpesvirus-6 reactivation and disease after allogeneic haematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis.
Kampouri E, Zamora D, Kiem ES, Liu W, Ibrahimi S, Blazevic RL, Lovas EA, Kimball LE, Huang ML, Jerome KR, Ueda Oshima M, Mielcarek M, Zerr DM, Boeckh MJ, Krantz EM, Hill JA. Kampouri E, et al. Among authors: ibrahimi s. Clin Microbiol Infect. 2023 Jul 31:S1198-743X(23)00354-3. doi: 10.1016/j.cmi.2023.07.026. Online ahead of print. Clin Microbiol Infect. 2023. PMID: 37532126
Humoral and cellular responses to SARS-CoV-2 vaccines before and after chimeric antigen receptor-modified T-cell therapy.
Gonzalez MA, Bhatti AM, Fitzpatrick K, Boonyaratanakornkit J, Huang ML, Campbell VL, Hecht J, Ibrahimi S, Wanner SN, Green DJ, Maloney DG, Gauthier J, Cowan AJ, Greninger AL, Krantz EM, Koelle DM, Hill JA. Gonzalez MA, et al. Among authors: ibrahimi s. Blood Adv. 2023 May 9;7(9):1849-1853. doi: 10.1182/bloodadvances.2022008338. Blood Adv. 2023. PMID: 36094846 Free PMC article. No abstract available.
Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy.
Kampouri E, Ibrahimi SS, Xie H, Wong ER, Hecht JB, Sekhon MK, Vo A, Stevens-Ayers TL, Green DJ, Gauthier J, Maloney DG, Perez A, Jerome KR, Leisenring WM, Boeckh MJ, Hill JA. Kampouri E, et al. Among authors: ibrahimi ss. Clin Infect Dis. 2024 Apr 10;78(4):1022-1032. doi: 10.1093/cid/ciad708. Clin Infect Dis. 2024. PMID: 37975819 Free PMC article.
Human Herpesvirus-6 Reactivation and Disease Are Infrequent in Chimeric Antigen Receptor T-cell Therapy Recipients.
Kampouri E, Krantz EM, Xie H, Ibrahimi SS, Kiem ES, Sekhon MK, Liang EC, Cowan AJ, Portuguese AJ, Green DJ, Albittar A, Huang JJ, Gauthier J, Pérez-Osorio AC, Jerome KR, Zerr D, Boeckh MJ, Hill JA. Kampouri E, et al. Among authors: ibrahimi ss. Blood. 2024 Apr 18:blood.2024024145. doi: 10.1182/blood.2024024145. Online ahead of print. Blood. 2024. PMID: 38635788
Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura.
Scully M, Antun A, Cataland SR, Coppo P, Dossier C, Biebuyck N, Hassenpflug WA, Kentouche K, Knöbl P, Kremer Hovinga JA, López-Fernández MF, Matsumoto M, Ortel TL, Windyga J, Bhattacharya I, Cronin M, Li H, Mellgård B, Patel M, Patwari P, Xiao S, Zhang P, Wang LT; cTTP Phase 3 Study Investigators. Scully M, et al. N Engl J Med. 2024 May 2;390(17):1584-1596. doi: 10.1056/NEJMoa2314793. N Engl J Med. 2024. PMID: 38692292 Clinical Trial.
Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.
Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Crotta A, Montheard S, Previtali A, Ogasawara K, Kamdar M. Abramson JS, et al. Among authors: ibrahimi s. Future Oncol. 2024 Mar 28. doi: 10.2217/fon-2023-0898. Online ahead of print. Future Oncol. 2024. PMID: 38547003 Free article. Review.
100 results